Revenue (Tables)

12 Months Ended

Dec. 31, 2023

Disaggregation of Revenue [Abstract]

The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.


	Year Ended December 31,
	2023						2022						2021
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	1,511	$	970	$	2,482	$	1,341	$	880	$	2,221	1,222		$	919	$	2,141
Urology	1,369		595		1,964		1,257		516		1,773		1,120		463		1,583
Neuromodulation	736		240		976		715		202		917		713		196		909
MedSurg	3,617		1,805		5,422		3,312		1,599		4,911		3,055		1,578		4,633
Interventional Cardiology Therapies	743		1,674		2,417		744		1,485		2,228		778		1,431		2,209
Watchman	1,155		119		1,274		915		103		1,019		729		100		829
Cardiac Rhythm Management	1,405		813		2,218		1,337		763		2,100		1,214		805		2,019
Electrophysiology	370		430		800		275		310		585		128		237		365
Cardiology	3,673		3,036		6,709		3,271		2,662		5,932		2,850		2,572		5,422
Peripheral Interventions	1,135		975		2,110		1,048		850		1,899		996		824		1,820
Cardiovascular	4,808		4,011		8,819		4,319		3,512		7,831		3,846		3,396		7,242
Other1	—		—		—		—		—		(60)		10		4		13
Total Net Sales	$	8,425	$	5,816	$	14,240	$	7,632	$	5,111	$	12,682	$	6,911	$	4,978	$	11,888

(1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.


	Year Ended December 31,
Geographic Regions	2023		2022		2021
U.S.	$	8,425	$	7,632	$	6,901
Europe, Middle East and Africa	2,856		2,526		2,518
Asia-Pacific	2,400		2,116		2,070
Latin America and Canada	560		469		386



Other1	—		(60)		13
Total Net Sales	$	14,240	$	12,682	$	11,888

Emerging Markets(2)	$	2,310	$	1,968	$	1,656

(2) Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior period amounts to conform to the current year's presentation.

Deferred Revenue